Results 1 to 10 of about 61,513 (245)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

Therapeutic Advances in Chronic Disease, 2019
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer, Henderik W. Frijlink   +9 more
doaj   +2 more sources

Levodopa influence on turning dynamics in people with Parkinson’s disease [PDF]

Scientific Reports
Turning behaviors are affected in people with Parkinson’s disease (PwPD) leading to falls and Freezing of Gait (FOG). Levodopa therapy is commonly recommended for PwPD to help alleviate motor symptoms.
Lakshmi Pillai, Reid D. Landes, Tuhin Virmani   +2 more
doaj   +2 more sources

A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa [PDF]

New England Journal of Medicine, 2000
BACKGROUND There is debate about whether the initial treatment for patients with Parkinson's disease should be levodopa or a dopamine agonist. METHODS In this prospective, randomized, double-blind study, we compared the safety and efficacy of the ...
Olivier Rascol, David J. Brooks, Amos D. Korczyn, Peter Paul De Deyn, Carl E Clarke, Anthony E. Lang   +5 more
openalex   +2 more sources

Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan

Frontiers in Pediatrics, 2021
Introduction: Post-synaptic dopamine receptor supersensitivity (DARSS) has been extensively researched by Dr. Masaya Segawa, who has investigated the efficacy of very-low-dose levodopa therapy (VLDT; 0.5–1 mg/kg/day).
Kyoko Hoshino, Kyoko Hoshino, Kyoko Hoshino, Masaharu Hayashi, Masaharu Hayashi, Masaharu Hayashi, Asayo Ishizaki, Asayo Ishizaki, Kazue Kimura, Kazue Kimura, Masaya Kubota, Masaya Kubota, Atsuo Nezu, Atsuo Nezu, Akihiro Yasuhara, Akihiro Yasuhara   +15 more
doaj   +1 more source

Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals

Movement Disorders, 2023
To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed.
S. Jost, Marie-Ann Kaldenbach, A. Antonini, P. Martínez-Martín, Lars Timmermann, P. Odin, R. Katzenschlager, R. Borgohain, A. Fasano, F. Stocchi, N. Hattori, P. Kukkle, M. Rodríguez‐Violante, C. Falup-Pecurariu, Sebastian Schade, J. Petry-Schmelzer, V. Metta, D. Weintraub, G. Deuschl, A. Espay, E. Tan, R. Bhidayasiri, Victor S. C. Fung, F. Cardoso, C. Trenkwalder, P. Jenner, K. Ray Chaudhuri, H. Dafsari   +27 more
semanticscholar   +1 more source

Gastrointestinal barriers to levodopa transport and absorption in Parkinson's disease

European Journal of Neurology, 2023
Levodopa is the gold standard for the symptomatic treatment of Parkinson's disease (PD). There are well documented motor and non‐motor fluctuations, however, that occur almost inevitably once levodopa is started after a variable period in people with PD.
V. Leta, L. Klingelhoefer, Katherine Longardner, M. Campagnolo, Hafize Çotur Levent, Federico Aureli, V. Metta, R. Bhidayasiri, G. Chung-Faye, C. Falup-Pecurariu, F. Stocchi, P. Jenner, T. Warnecke, K. Ray Chaudhuri   +13 more
semanticscholar   +1 more source

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program

Frontiers in Neurology, 2022
BackgroundWhile treatment with levodopa remains the cornerstone of Parkinson's disease (PD) management, chronic oral therapy is often associated with the development of motor complications, that correlate to fluctuating levodopa plasma concentrations ...
Peter A. LeWitt, Fabrizio Stocchi, David Arkadir, Yoseph Caraco, Liat Adar, Itay Perlstein, Ryan Case, Nir Giladi   +7 more
doaj   +1 more source

Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies

Cells, 2022
The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement therapy using levodopa during the course of the disease’s progression ...
Destany K. Kwon, M. Kwatra, Jing Wang, H. Ko   +3 more
semanticscholar   +1 more source

Mechanisms of peripheral levodopa resistance in Parkinson’s disease

npj Parkinson's Disease, 2022
Parkinson’s disease (PD) is an increasingly common neurodegenerative condition. The disease has a significant negative impact on quality of life, but a personalized management approach can help reduce disability. Pharmacotherapy with levodopa remains the
Milan Beckers, B. Bloem, M. Verbeek
semanticscholar   +1 more source

Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review

Advances in Nutrition, 2021
Although levodopa remains the most effective drug for symptomatic management of Parkinson's Disease (PD), treatment during advanced disease stages may raise unpredictable motor fluctuations and other complications.
Jikke T Boelens Keun, I. Arnoldussen, C. Vriend, O. van de Rest   +3 more
semanticscholar   +1 more source